टैमोक्सीफेन के इंटरैक्शन

Bradycardia may increase the risk of QT prolongation which may lead to severe ventricular arrhythmias, including torsade de pointes, especially in patients with risk factors such as use of QTc prolonging drugs [see Adverse Reactions ( 6.2 )] . (आइवाब्राडिन लेबल, चेतावनियां और सावधानियां)

For women with DCIS and for the reduction in breast cancer incidence in women at high risk, tamoxifen is contraindicated in women who require concomitant warfarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Avoid the use of FANAPT in combination with any other drugs that prolong the QT interval [see Warnings and Precautions (5.3) ] . (इलोपेरिडोन लेबल, दवाओं के इंटरैक्शन)

This risk which can be fatal should be considered in patients with certain cardiovascular disorders including known QT prolongation or history torsades de pointes, those with proarrhythmic conditions, and with other drugs that prolong the QT interval. (एज़िथ्रोमाइसिन लेबल, चेतावनियां और सावधानियां)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

For women with DCIS and for the reduction in breast cancer incidence in women at high risk, tamoxifen is contraindicated in women who require concomitant warfarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Anastrozole and letrozole: Should not be used in combination with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

For women with DCIS and for the reduction in breast cancer incidence in women at high risk, tamoxifen is contraindicated in women who require concomitant warfarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

For women with DCIS and for the reduction in breast cancer incidence in women at high risk, tamoxifen is contraindicated in women who require concomitant warfarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Concomitant use of COMPLERA with drugs with a known risk to prolong the QTc interval of the electrocardiogram may increase the risk of Torsade de Pointes. (एमट्रिसिटाबिन, रिल्पिविरिन और टेनोफोविर लेबल, चेतावनियां और सावधानियां)

Reserve the combination of amiodarone with other antiarrhythmic therapies that prolong the QTc to patients with life-threatening ventricular arrhythmias who are incompletely responsive to a single agent. (एमियोडेरोन लेबल, चेतावनियां और सावधानियां)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Avoid coadministration of oxaliplatin injection with medicinal products with a known potential to prolong the QT interval. (ऑक्सालिप्लैटिन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Tamoxifen: Concomitant use of chloroquine with drugs known to induce retinal toxicity such as tamoxifen is not recommended (see WARNINGS ). (क्लोरोक्वीन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

…drugs, ziprasidone is contraindicated: • in patients with a known history of QT prolongation (including congenital long QT syndrome) • in patients with recent acute myocardial infarction • in patients with uncompensated heart failure Pharmacokinetic/pharmacodynamic studies between ziprasidone and other drugs that prolong the QT interval have not been performed. (ज़िप्रासिडोन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Certain conditions may increase the risk for torsade de pointes or sudden death such as (1) bradycardia; (2) hypokalemia or hypomagnesemia; (3) concomitant use of other drugs that prolong the QTc interval; and (4) presence of congenital prolongation of the QT interval [see Warnings and Precautions ( 5.8 ), Clinical Pharmacology (12.2) ]. (टेट्राबेनाज़िन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

For women with DCIS and for the reduction in breast cancer incidence in women at high risk, tamoxifen is contraindicated in women who require concomitant warfarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Use with Drugs that Prolong QT Interval and Antiarrhythmic Agents The use of dofetilide in conjunction with other drugs that prolong the QT interval has not been studied and is not recommended. (डोफेटिलाइड लेबल, चेतावनियां)

CONTRAINDICATIONS Thioridazine hydrochloride tablet use should be avoided in combination with other drugs that are known to prolong the QTc interval and in patients with congenital long QT syndrome or a history of cardiac arrhythmias. (थायोरिडाज़िन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Avoid coadministration of VOTRIENT with drugs known to prolong the QT/QTc interval. (पाज़ोपैनिब लेबल, दवाओं के इंटरैक्शन)

The use of WAKIX should be avoided in patients with known QT prolongation or in combination with other drugs known to prolong the QT interval [see Drug Interactions ( 7.1 )]. (पिटोलिसेंट लेबल, चेतावनियां और सावधानियां)

Because pimozide prolongs the QT interval of the electrocardiogram it is contraindicated in patients with congenital long QT syndrome, patients with a history of cardiac arrhythmias, patients taking other drugs which prolong the QT interval of the electrocardiogram or patients with known hypokalemia or hypomagnesemia (see also PRECAUTIONS - DRUG INTERACTIONS ). (पिमोज़ाइड लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

• Avoid use with other antiarrhythmic agents or drugs that prolong the QT interval. (प्रोपाफेनोन लेबल, चेतावनियां और सावधानियां)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

(See DOSAGE and ADMINISTRATION. ) Because of the risk of QT prolongation and the potential for torsades de pointes, the use of FOSCAVIR should be avoided in combination with agents known to prolong the QT interval including Class IA (e.g., quinidine or procainamide) or Class III (e.g., dofetilide, amiodarone, sotalol) antiarrhythmic agents, phenothiazines, tricyclic… (फॉस्कारनेट लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Avoid co-administration of CONTEPO with drugs known to prolong the QT interval. (फॉस्फोमाइसिन लेबल, दवाओं के इंटरैक्शन)

For women with DCIS and for the reduction in breast cancer incidence in women at high risk, tamoxifen is contraindicated in women who require concomitant warfarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Coadministration of other drugs known to prolong the QT interval and which are metabolized via the enzyme CYP3A4 such as erythromycin, pimozide, and quinidine are contraindicated in patients receiving fluconazole. (फ्लुकोनाज़ोल लेबल, निषेध (कॉन्ट्राइंडिकेशन))

For women with DCIS and for the reduction in breast cancer incidence in women at high risk, tamoxifen is contraindicated in women who require concomitant warfarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Examples diazepam, alprazolam, alcohol Drugs that Prolong QTc Interval Clinical Impact The concomitant use of other drugs which prolong the QTc interval with REMERON/REMERONSolTab, increase the risk of QT prolongation and/or ventricular arrhythmias (e.g., Torsades de Pointes). (मिर्टाज़ापिन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

For women with DCIS and for the reduction in breast cancer incidence in women at high risk, tamoxifen is contraindicated in women who require concomitant warfarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Anastrozole and letrozole: Should not be used in combination with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval ( 5.11 , 8.5 ) (लेवोफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

SOLTAMOX is contraindicated in patients who require concomitant warfarin therapy or have a history of deep vein thrombosis or pulmonary embolus if the indication for treatment is either reduction of breast cancer incidence in high-risk patients or risk reduction of invasive breast cancer after treatment of DCIS [see Warnings and Precautions (5.2) and Drug Interactions… (टैमोक्सीफेन लेबल, निषेध (कॉन्ट्राइंडिकेशन))

Avoid concomitant use of VEPPANU with strong CYP3A inhibitors or drugs known to prolong the QTc interval. (वेपडेजेस्ट्रेंट लेबल, चेतावनियां और सावधानियां)

Avoid the concomitant use of drugs known to prolong the QTc interval. (सर्ट्रालिन लेबल, दवाओं के इंटरैक्शन)

Avoid use in patients with known prolongation, those with hypokalemia, and with other drugs that prolong the QT interval. (सिप्रोफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Inducers of CYP3A4 Strong CYP3A4 inducers should not be used with tamoxifen. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Therefore, PLAQUENIL is not recommended in patients taking other drugs that have the potential to prolong the QT interval. (हाइड्रॉक्सीक्लोरोक्वीन लेबल, चेतावनियां और सावधानियां)

For women with DCIS and for the reduction in breast cancer incidence in women at high risk, tamoxifen is contraindicated in women who require concomitant warfarin-type anticoagulant therapy or in women with a history of deep vein thrombosis or pulmonary embolus. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Monitor QT interval when administering FORANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (आइसोफ्लुरेन लेबल, चेतावनियां और सावधानियां)

MAO inhibitors, tricyclic antidepressants and drugs that prolong the QTc interval may potentiate effect on the cardiovascular system. (आरफॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

Percent Change in BMD from Baseline to 24 months, Exemestane vs. Control 1 IES 027 BMD Exemestane N=29 Tamoxifen 1 N=38 Exemestane N=59 Placebo 1 N=65 Lumbar spine (%) -3.1 -0.2 -3.5 -2.4 Femoral neck (%) -4.2 -0.3 -4.6 -2.6 During adjuvant treatment with exemestane, women with osteoporosis or at risk of osteoporosis should have their bone mineral density formally… (एक्सेमेस्टेन लेबल, चेतावनियां और सावधानियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

QT Prolongation: Monitor for prolonged QT intervals in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, and electrolyte abnormalities. (एरिबुलिन लेबल, चेतावनियां और सावधानियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Use olanzapine and fluoxetine capsules with caution in combination with other drugs that prolong the QT interval ( 4.2 , 5.20 , 7.7 , 7.8 ) 7.1 Monoamine Oxidase Inhibitors (MAOIs) [See Dosage and Administration ( 2.4 , 2.5 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.6 )] . (ओलैंज़ापिन और फ्लुओक्सेटिन लेबल, दवाओं के इंटरैक्शन)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

…Class 1A antiarrythmics (e.g., quinidine, procainamide) or Class III antiarrythmics (e.g., amiodarone, sotalol), antipsychotic medications (e.g., ziprasidone, chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval (e.g., pentamidine, levomethadyl acetate, methadone). (क्वेटियापिन लेबल, चेतावनियां और सावधानियां)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (गोसेरेलिन लेबल, चेतावनियां और सावधानियां)

Drug-Laboratory Test Interactions There are postmarketing reports of T 4 elevations in postmenopausal patients taking tamoxifen that may be explained by increases in thyroid-binding globulin. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (ट्रिप्टोरेलिन लेबल, चेतावनियां और सावधानियां)

Carefully monitor cardiac rhythm when administering SUPRANE to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (डेसफ्लुरेन लेबल, चेतावनियां और सावधानियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

…cardiac disease, 3) treatment with Class I and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval (see PRECAUTIONS, Drug Interactions ), and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs… (ड्रोपेरिडोल लेबल, चेतावनियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Reduction of Efficacy of Tamoxifen Some studies have shown that the efficacy of tamoxifen, as measured by the risk of breast cancer relapse/mortality, may be reduced with concomitant use of paroxetine as a result of paroxetine’s irreversible inhibition of CYP2D6 and lower blood levels of tamoxifen [see Drug Interactions ( 7.1 )]. (पैरोक्सेटिन लेबल, चेतावनियां और सावधानियां)

…combination with other drugs that are known to prolong QTc including Class 1A (e.g., quinidine, procainamide) or Class III (e.g., amiodarone, sotalol) antiarrhythmic medications, antipsychotic medications (e.g., chlorpromazine, thioridazine), antibiotics (e.g., gatifloxacin, moxifloxacin), or any other class of medications known to prolong the QTc interval. (पैलिपेरिडोन लेबल, चेतावनियां और सावधानियां)

Drugs that Prolong QT: Use with caution in patients who are at significant risk of developing QTc prolongation. (पैसिरियोटाइड लेबल, दवाओं के इंटरैक्शन)

Anti-Arrhythmic Drugs, QT Prolonging Drugs, Drugs that may Decrease Heart Rate PONVORY has not been studied in patients taking QT prolonging drugs. (पोनेसिमोड लेबल, दवाओं के इंटरैक्शन)

QT Interval Prolonging Drugs The pharmacodynamic interaction potential to prolong the QT interval of the electrocardiogram between Primaquine phosphate Tablets and other drugs that effect cardiac conduction is unknown. (प्राइमाक्वीन लेबल, दवाओं के इंटरैक्शन)

Drug-Laboratory Test Interactions There are postmarketing reports of T 4 elevations in postmenopausal patients taking tamoxifen that may be explained by increases in thyroid-binding globulin. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

…prolonged QT interval, 3) treatment with Class 1 and Class III antiarrhythmics, 4) treatment with monoamine oxidase inhibitors (MAOI's), 5) concomitant treatment with other drug products known to prolong the QT interval and 6) electrolyte imbalance, in particular hypokalemia and hypomagnesemia, or concomitant treatment with drugs (e.g., diuretics) that may cause electrolyte… (फेंटानिल लेबल, चेतावनियां और सावधानियां)

…Antidepressants, QTc Prolonging Drugs Formoterol, as with other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (फॉर्मोटेरोल लेबल, दवाओं के इंटरैक्शन)

Use with caution in combination with other drugs that prolong the QT interval ( 4.2 , 5.11 , 7.7 , 7.8 ) 7.1 Monoamine Oxidase Inhibitors (MAOI) [See Dosage and Administration ( 2.9 , 2.10 ), Contraindications ( 4.1 ), and Warnings and Precautions ( 5.2 )] . (फ्लुओक्सेटिन लेबल, दवाओं के इंटरैक्शन)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

Drugs that Prolong the QT interval QT prolongation has been reported with metronidazole, a component of bismuth subcitrate potassium, metronidazole and tetracycline hydrochloride, particularly when administered with drugs with the potential for prolonging the QT interval. (बिस्मथ सबसाइट्रेट, मेट्रोनिडाज़ोल और टेट्रासाइक्लिन लेबल, चेतावनियां और सावधानियां)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (ब्यूप्रेनॉर्फिन लेबल, चेतावनियां और सावधानियां)

The risk of combining buprenorphine with other QT-prolonging agents is not known. (ब्यूप्रेनॉर्फिन और नालोक्सोन लेबल, चेतावनियां और सावधानियां)

Drugs that require metabolic activation by CYP2D6 to be effective (e.g., tamoxifen) theoretically could have reduced efficacy when administered concomitantly with inhibitors of CYP2D6 such as bupropion. (ब्यूप्रोपियॉन लेबल, दवाओं के इंटरैक्शन)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

There is little or no experience with high exposure, concomitant dosing with other QT-prolonging drugs, or potassium channel variants resulting in a long QT interval. [See Warnings & Precautions ( 5.6 )] To minimize risk, the lowest effective dose should always be used. (मिफेप्रिस्टोन लेबल, चेतावनियां और सावधानियां)

Drugs that Prolong the QT Interval QT prolongation has been reported, particularly when metronidazole was administered with drugs with the potential for prolonging the QT interval. (मेट्रोनिडाज़ोल लेबल, दवाओं के इंटरैक्शन)

Drug-Laboratory Test Interactions There are postmarketing reports of T 4 elevations in postmenopausal patients taking tamoxifen that may be explained by increases in thyroid-binding globulin. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Other Drugs that Prolong the QTc Interval Coadministration of other drugs known to alter cardiac conduction (e.g., anti-arrhythmic or beta-adrenergic blocking agents, calcium channel blockers, antihistamines or H 1 -blocking agents, tricyclic antidepressants and phenothiazines) might also contribute to a prolongation of the QTc interval. (मेफ्लोक्वीन लेबल, दवाओं के इंटरैक्शन)

Pharmacokinetic studies between moxifloxacin and other drugs that prolong the QT interval such as cisapride, erythromycin, antipsychotics, and tricyclic antidepressants have not been performed. (मॉक्सीफ्लॉक्सासिन लेबल, चेतावनियां और सावधानियां)

…like other beta 2 -agonists, should be administered with extreme caution to patients being treated with monoamine oxidase inhibitors, tricyclic antidepressants, or drugs known to prolong the QTc interval or within 2 weeks of discontinuation of such agents, because the effect of adrenergic agonists on the cardiovascular system may be potentiated by these agents. (यूमेक्लिडिनियम और विलैंटेरोल लेबल, दवाओं के इंटरैक्शन)

In healthy subjects, 75 mg once daily and 300 mg once daily (3 times and 12 times the dose in EDURANT) have been shown to prolong the QTc interval of the electrocardiogram. (रिल्पिविरिन लेबल, चेतावनियां और सावधानियां)

QT Interval Prolongation The overall analysis of ECG data in pediatric patients indicates that the concomitant use of Rocuronium Bromide Injection with general anesthetic agents can prolong the QTc interval [see Clinical Studies ( 14.3 )]. (रोक्यूरोनियम लेबल, चेतावनियां और सावधानियां)

Drug-Laboratory Test Interactions There are postmarketing reports of T 4 elevations in postmenopausal patients taking tamoxifen that may be explained by increases in thyroid-binding globulin. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Drug-Laboratory Test Interactions There are postmarketing reports of T 4 elevations in postmenopausal patients taking tamoxifen that may be explained by increases in thyroid-binding globulin. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Drug-Laboratory Test Interactions There are postmarketing reports of T 4 elevations in postmenopausal patients taking tamoxifen that may be explained by increases in thyroid-binding globulin. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Hypercalcemia in Patients with Metastatic Breast Cancer As with other additive hormonal therapy (estrogens and androgens), hypercalcemia has been reported in some breast cancer patients with bone metastases within a few weeks of starting treatment with tamoxifen. (टैमोक्सीफेन लेबल, चेतावनियां और सावधानियां)

TYKERB may prolong the QT interval in some patients. (लैपाटिनिब लेबल, चेतावनियां और सावधानियां)

Risk of QT Prolongation : Lofexidine tablets prolong the QT interval. (लोफेक्सिडिन लेबल, चेतावनियां और सावधानियां)

Caution should be exercised when JUXTAPID is used with other medications known to have potential for hepatotoxicity, such as isotretinoin, amiodarone, acetaminophen (>4 g/day for ≥3 days/week), methotrexate, tetracyclines, and tamoxifen. (लोमिटापाइड लेबल, चेतावनियां और सावधानियां)

Effect on QT/QTc Interval: Androgen deprivation therapy may prolong the QT interval. (ल्यूप्रोलाइड लेबल, चेतावनियां और सावधानियां)

Tamoxifen Concomitant use of tamoxifen and a cyclophosphamide-containing chemotherapy regimen may increase the risk of thromboembolic complications. (साइक्लोफॉस्फामाइड लेबल, दवाओं के इंटरैक्शन)

Avoid use of Citalopram Capsules in patients with congenital long QT syndrome, bradycardia, hypokalemia or hypomagnesemia, recent acute myocardial infarction, or uncompensated heart failure and patients taking other drugs that prolong the QTc interval. (सिटालोप्राम लेबल, चेतावनियां और सावधानियां)

QT Interval Prolongation and V entricular A rr h ythmia Decreases in serum calcium can also prolong the QT interval, potentially resulting in ventricular arrhythmia. (सिनाकैल्सेट लेबल, चेतावनियां और सावधानियां)

Drugs that Prolong QT Interval SUTENT is associated with QTc interval prolongation [see Warnings and Precautions (5.3) , Clinical Pharmacology (12.2) ] . (सुनिटिनिब लेबल, दवाओं के इंटरैक्शन)

Caution should be exercised when administering sevoflurane to susceptible patients (e.g., patients with congenital Long QT Syndrome or patients taking drugs that can prolong the QT interval). (सेवोफ्लुरेन लेबल, चेतावनियां)

Additive to other QT-prolonging drugs ( 7.1 , 7.2 ) (सोटालोल लेबल, दवाओं के इंटरैक्शन)

Monitor electrolytes and electrocardiograms in patients with congestive heart failure, bradyarrhythmias, drugs known to prolong the QT interval, including Class Ia and III antiarrhythmics. (सोराफेनिब लेबल, चेतावनियां और सावधानियां)

This observation should be considered in making clinical decisions regarding patient monitoring when prescribing HYSINGLA ER in patients with congestive heart failure, bradyarrhythmias, electrolyte abnormalities, or who are taking medications that are known to prolong the QTc interval. (हाइड्रोकोडोन लेबल, चेतावनियां और सावधानियां)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

Strong Inhibitors of CYP2D6 The impact on the efficacy of tamoxifen with co-administration of strong CYP2D6 inhibitors (e.g., paroxetine) is not well established. (टैमोक्सीफेन लेबल, दवाओं के इंटरैक्शन)

…Having No Clinically Important Interactions with PRISTIQ Based on pharmacokinetic studies, no dosage adjustment is required for drugs that are mainly metabolized by CYP3A4 (e.g., midazolam), or for drugs that are metabolized by both CYP2D6 and CYP3A4 (e.g., tamoxifen, aripiprazole), when administered concomitantly with PRISTIQ [see Clinical Pharmacology (12.3) ]. (डेसवेनलाफैक्सिन लेबल, दवाओं के इंटरैक्शन)